Oxidative Phosphorylation & Electron Transport Chain

The terminal stage of aerobic energy metabolism, where electrons from NADH and FADH₂ flow down the respiratory chain to molecular oxygen, and the released energy is captured as ATP. This is the single largest ATP-yielding process in the cell and a perennial NEET PG favourite for its inhibitors, uncouplers and yield calculations.

Orientation & definitions

Oxidative phosphorylation (OXPHOS) = synthesis of ATP coupled to the transfer of electrons from reduced coenzymes (NADH, FADH₂) to oxygen via the electron transport chain (ETC). It occurs on the inner mitochondrial membrane (IMM) and is the final common pathway of glucose, fatty acid and amino acid catabolism.

Two physically distinct but coupled events:

Process	What happens	Location
Electron transport (respiration)	Electrons pass through complexes I–IV to O₂; energy pumps H⁺ out of matrix	Inner mitochondrial membrane
Phosphorylation	Proton-motive force drives ATP synthase (Complex V) to make ATP	Inner mitochondrial membrane (F₁ in matrix)

The two are joined by the proton-motive force (pmf) — the electrochemical H⁺ gradient. This linkage is the basis of the chemiosmotic theory (Peter Mitchell, Nobel Prize 1978).

High-yield: ETC + ATP synthase are located on the inner mitochondrial membrane. The IMM is impermeable to H⁺, NADH and most ions — this impermeability is what allows the proton gradient to be maintained.

The respiratory chain — Complexes I to IV

Electrons enter at two points and converge on coenzyme Q, then cytochrome c, then O₂.

Stepwise electron flow:

NADH → Complex I → CoQ → Complex III → cyt c → Complex IV → O₂ FADH₂ (succinate) → Complex II → CoQ → Complex III → cyt c → Complex IV → O₂

Complex	Name	Function	Prosthetic groups	Pumps H⁺?
I	NADH–CoQ oxidoreductase (NADH dehydrogenase)	NADH → CoQ	FMN, Fe-S centres	Yes (4 H⁺)
II	Succinate–CoQ oxidoreductase (succinate dehydrogenase)	FADH₂/succinate → CoQ	FAD, Fe-S, cyt b₅₆₀	No
III	CoQ–cyt c oxidoreductase (cytochrome bc₁)	CoQ → cyt c	cyt b, cyt c₁, Fe-S (Rieske)	Yes (4 H⁺)
IV	Cytochrome c oxidase	cyt c → O₂ → H₂O	cyt a, cyt a₃, Cu (CuA, CuB)	Yes (2 H⁺)
V	ATP synthase	Uses pmf to make ATP	F₀ (membrane), F₁ (matrix)	Lets H⁺ back in

Key carriers worth remembering:

• Coenzyme Q (ubiquinone) — the only non-protein, lipid-soluble, mobile carrier; freely diffuses within the membrane; the convergence point for electrons from Complex I and Complex II. It can carry electrons one at a time via the semiquinone radical.
• Cytochrome c — small, water-soluble peripheral protein on the outer face of the IMM; mobile carrier between III and IV. Its release into the cytosol triggers apoptosis (activates Apaf-1 → caspase-9 → caspase-3).
• Iron–sulphur (Fe-S) clusters are present in complexes I, II and III. Aconitase of the TCA cycle is also an Fe-S enzyme (frequent distractor).

High-yield: Complex II (succinate dehydrogenase) is the only ETC enzyme that is also a TCA-cycle enzyme and the only complex that does NOT pump protons. Hence FADH₂-fed electrons yield less ATP than NADH-fed electrons.

High-yield: Cytochromes contain haem (iron); they transfer electrons by Fe²⁺ ⇌ Fe³⁺ cycling. Complex IV additionally uses copper centres and is the only complex that reacts directly with O₂.

Mnemonic for the chain order: "I → Q → III → C → IV" — "I Quietly Cooked" (Complex I, Q/CoQ, III, Cytochrome c, IV).

Chemiosmotic theory & ATP synthase (Complex V)

As electrons traverse complexes I, III and IV, protons are pumped from the matrix into the intermembrane space, generating:

1. A chemical gradient (ΔpH — more acidic outside).
2. An electrical gradient (Δψ — positive outside).

Together these constitute the proton-motive force. Protons flow back into the matrix through the F₀ channel of ATP synthase; this flow rotates the γ-subunit, driving conformational changes in the F₁ head (α₃β₃) that phosphorylate ADP — the binding-change mechanism (Paul Boyer & John Walker, Nobel 1997).

High-yield: ATP synthase = F₁F₀-ATPase. F₀ is the membrane-embedded proton channel (the "o" is for oligomycin sensitivity); F₁ is the matrix knob that synthesises ATP. Oligomycin blocks F₀, halting both proton flow and ATP synthesis.

Roughly 4 H⁺ are required per ATP synthesised and exported (≈3 for synthesis + 1 for ATP/ADP and Pi transport via the adenine nucleotide translocase and phosphate carrier).

P/O ratio and ATP yield

The P/O ratio = molecules of ADP phosphorylated to ATP per atom of oxygen reduced (per pair of electrons).

Substrate / electron donor	Entry point	P/O ratio (modern)	Older value
NADH	Complex I	~2.5	3
FADH₂ / succinate	Complex II	~1.5	2

Modern consensus values: each NADH = ~2.5 ATP; each FADH₂ = ~1.5 ATP. Older textbooks use 3 and 2 — NEET PG questions may use either, so know both and read the stem.

Total ATP from one glucose (complete aerobic oxidation):

Stage	Yield (modern)	Yield (older)
Glycolysis: 2 ATP (net) + 2 NADH (cytosolic)	2 + (2×1.5 or 2.5)*	2 + (4 or 6)*
Pyruvate → acetyl-CoA: 2 NADH	5	6
TCA cycle (×2): 6 NADH, 2 FADH₂, 2 GTP	20	24
Total	~30–32 ATP	36–38 ATP

*Cytosolic NADH yield depends on the shuttle used:

• Malate–aspartate shuttle (heart, liver, kidney) → NADH delivered as matrix NADH → ~2.5 ATP each → total ~32.
• Glycerol-3-phosphate shuttle (skeletal muscle, brain) → electrons enter as FADH₂ → ~1.5 ATP each → total ~30.

High-yield: Net ATP per glucose = ~30–32 (modern) or 36–38 (older). The difference (30 vs 32) hinges on which shuttle transfers cytosolic NADH across the IMM.

High-yield: The glycerophosphate shuttle yields less ATP because cytosolic NADH electrons enter at the level of FADH₂ (bypassing Complex I).

Inhibitors of the ETC — the most tested table

Classify by site of action. A blocked site causes carriers upstream to become reduced and those downstream to become oxidised.

Inhibitor	Site / target	Type
Rotenone, amobarbital (amytal), piericidin, MPP⁺	Complex I	Electron transport inhibitor
Carboxin, TTFA, malonate (competitive)	Complex II / succinate DH	Electron transport inhibitor
Antimycin A, BAL (dimercaprol)	Complex III	Electron transport inhibitor
Cyanide (CN⁻), carbon monoxide (CO), azide (N₃⁻), H₂S	Complex IV (cyt a/a₃)	Electron transport inhibitor
Oligomycin	F₀ of ATP synthase	ATP synthase inhibitor
Atractyloside, bongkrekic acid	Adenine nucleotide translocase	Transport inhibitor

High-yield: Cyanide and CO inhibit Complex IV (cytochrome c oxidase, cyt aa₃) — the classic cause of histotoxic hypoxia (high venous O₂, lactic acidosis, normal/high SpO₂). MPP⁺ (from MPTP) inhibits Complex I and causes a parkinsonian syndrome.

High-yield: Rotenone (an insecticide/fish poison) = Complex I; Antimycin A = Complex III; Malonate = competitive inhibitor of succinate dehydrogenase (Complex II).

Mnemonic for Complex inhibitors: "Really A Cute Oligo" — Rotenone(I) → Antimycin(III) → Cyanide/CO(IV) → Oligomycin(V). (Complex II by malonate/carboxin separately.)

Cyanide poisoning management flow:

Remove source → 100% O₂ → Hydroxocobalamin (binds CN⁻ → cyanocobalamin) ± Sodium thiosulphate (→ thiocyanate, renally excreted) ± Amyl/sodium nitrite (induces methaemoglobin → binds CN⁻)

Uncouplers & ionophores

An uncoupler dissipates the proton gradient without going through ATP synthase, so electron transport (and O₂ consumption) continues at high rate but ATP synthesis falls and the energy is released as heat.

Agent	Mechanism / note
2,4-Dinitrophenol (DNP)	Lipophilic weak acid; shuttles H⁺ across IMM. Classic synthetic uncoupler; old weight-loss drug — banned due to fatal hyperthermia
Thermogenin / UCP1	Physiological proton channel in brown adipose tissue mitochondria; mediates non-shivering thermogenesis in neonates & hibernators
Aspirin / salicylates (toxic dose)	Uncoupling → hyperthermia in salicylate poisoning
Valinomycin	K⁺ ionophore (not a true uncoupler but disrupts membrane potential)
FCCP, CCCP	Research uncouplers (protonophores)

High-yield: Brown fat thermogenesis uses thermogenin (UCP1), abundant in neonates (interscapular region) for heat production. Brown fat is brown because of its high mitochondrial/cytochrome content.

High-yield: Uncouplers increase O₂ consumption and substrate oxidation but decrease ATP yield and increase heat → hyperthermia. Contrast with inhibitors, which decrease O₂ consumption.

Distinguishing the three insults:

1. ETC inhibitor → O₂ consumption ↓, ATP ↓.
2. Uncoupler → O₂ consumption ↑, ATP ↓, heat ↑.
3. ATP synthase inhibitor (oligomycin) → O₂ consumption ↓ (because gradient builds and back-pressure stalls pumping), ATP ↓ — unless an uncoupler is added, which restores respiration (a classic experiment).

Clinical correlates — mitochondrial disorders & ROS

OXPHOS defects produce mitochondrial diseases, which are typically maternally inherited (mitochondrial DNA), show heteroplasmy and a threshold effect, and hit high-energy tissues (brain, muscle, heart, eye, endocrine).

Disorder	Key features
LHON (Leber hereditary optic neuropathy)	Complex I mutation; sudden bilateral central vision loss in young males
MELAS	Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes
MERRF	Myoclonic Epilepsy with Ragged Red Fibres
Leigh syndrome	Subacute necrotising encephalomyelopathy; Complex I/IV or PDH defects
Kearns–Sayre syndrome	Progressive external ophthalmoplegia, retinitis pigmentosa, heart block

Reactive oxygen species (ROS): ~1–2% of electrons leak (mainly at Complex I and III) to form superoxide (O₂•⁻). Defences: superoxide dismutase (SOD) → H₂O₂ → catalase and glutathione peroxidase (uses selenium + GSH). Failure underlies oxidative stress, ageing and ischaemia–reperfusion injury.

High-yield: Ragged red fibres on modified Gomori trichrome stain = hallmark of mitochondrial myopathy. Mitochondrial inheritance is maternal, with heteroplasmy explaining variable phenotype.

Diagnosis & investigations (applied)

• Cyanide toxicity: clinical + elevated lactate (anion-gap metabolic acidosis), narrowed arterio-venous O₂ difference (high venous O₂ sat), smell of bitter almonds (in ~40%). Confirm with whole-blood cyanide level (not needed before treatment).
• Mitochondrial disease: serum/CSF lactate ↑, lactate:pyruvate ratio ↑, muscle biopsy (ragged red fibres, COX-negative fibres), mtDNA sequencing, MRI brain (Leigh — basal ganglia/brainstem lesions).
• Brown fat / UCP1: seen as PET-avid (FDG) fat in supraclavicular regions — a classic incidental finding.

Key differentials & "look-alike" concepts

Confusable pair	Distinguishing point
Inhibitor vs uncoupler	Inhibitor ↓O₂ use; uncoupler ↑O₂ use, ↑heat
Substrate-level vs oxidative phosphorylation	Substrate-level = direct, O₂-independent (glycolysis PGK/PK, TCA succinyl-CoA synthetase); OXPHOS = O₂-dependent, ETC-coupled
Complex I vs Complex II electrons	Complex I (NADH) = 2.5 ATP; Complex II (FADH₂) = 1.5 ATP
Histotoxic vs hypoxic vs anaemic hypoxia	Histotoxic (cyanide) = cells can't use O₂ → high venous O₂

High-yield: During hypoxia/ischaemia, OXPHOS fails → cells revert to anaerobic glycolysis → lactic acidosis. ATP synthase can run in reverse (hydrolysing ATP to pump protons) to preserve membrane potential — a cause of rapid ATP depletion in ischaemia.

Recently asked / exam angle

• Site of action of specific inhibitors (rotenone, antimycin A, oligomycin, cyanide) — the single most repeated theme. Expect "which complex does X inhibit?"
• DNP / uncoupler effect on O₂ consumption and ATP — and DNP as a banned slimming agent causing fatal hyperthermia.
• Thermogenin (UCP1) in brown adipose tissue and neonatal thermogenesis.
• Net ATP per glucose and the shuttle difference (30 vs 32; malate–aspartate vs glycerophosphate).
• Mobile electron carriers: CoQ (lipid-soluble) and cytochrome c (water-soluble); cytochrome c release → apoptosis.
• Complex II as the only non-proton-pumping, TCA-shared complex.
• MPTP/MPP⁺ → Complex I → parkinsonism; LHON = Complex I.
• Chemiosmotic theory — Peter Mitchell; binding-change mechanism — Boyer/Walker.
• Cytochrome c oxidase (Complex IV) uses copper and reacts with O₂; inhibited by CO/CN⁻/azide/H₂S.
• P/O ratio definition and values.

Rapid revision

1. ETC and ATP synthase live on the inner mitochondrial membrane; the IMM's impermeability sustains the proton gradient.
2. Electron path: NADH → I → CoQ → III → cyt c → IV → O₂; succinate/FADH₂ enters at Complex II.
3. Complex II is the only complex that does not pump protons and the only one shared with the TCA cycle.
4. CoQ = lipid-soluble mobile carrier (convergence point); cyt c = water-soluble mobile carrier whose cytosolic release triggers apoptosis.
5. Proton-pumping complexes = I, III, IV; protons re-enter via ATP synthase (Complex V).
6. NADH ≈ 2.5 ATP, FADH₂ ≈ 1.5 ATP (old values 3 and 2).
7. Net glucose ATP = ~30–32 (modern) / 36–38 (old); shuttle decides 30 vs 32.
8. Rotenone → I, Antimycin A → III, Cyanide/CO/azide → IV, Oligomycin → F₀ of V; malonate → II.
9. Cyanide = histotoxic hypoxia, high venous O₂, lactic acidosis; treat with hydroxocobalamin + thiosulphate ± nitrites.
10. DNP uncouples → ↑O₂ use, ↓ATP, ↑heat (fatal hyperthermia; banned diet drug).
11. Thermogenin (UCP1) uncouples in brown fat for neonatal non-shivering thermogenesis.
12. Mitochondrial diseases are maternally inherited, show heteroplasmy, cause ragged red fibres — e.g. LHON (I), MELAS, MERRF, Leigh, Kearns–Sayre.